Home RXi Pharmaceuticals Announces Initiation of Phase 2a Keloid Study
 

Keywords :   


RXi Pharmaceuticals Announces Initiation of Phase 2a Keloid Study

2014-04-30 11:16:46| Biotech - Topix.net

RXI-109 is an sd-rxRNA compound that targets connective tissue growth factor and is being developed for the treatment of abnormal dermal scars, such as hypertrophic scars and keloids, in conjunction with scar or keloid revision surgery.

Tags: study phase announces initiation

Category:Biotechnology and Pharmaceuticals

Latest from this category

All news

»
01.11Atlantic Tropical Weather Outlook
01.11Eastern North Pacific Tropical Weather Outlook
01.11Boeing makes 38% pay rise offer in bid to end strike
01.11The house paints that promise much more than colour
01.11Eastern North Pacific Tropical Weather Outlook
01.11Atlantic Tropical Weather Outlook
01.11Technology adoption: What's on the ag tech horizon for 2025
01.11Technology adoption: What's on the ag tech horizon for 2025
More »